Takeda Constructs High-Containment Facility in Ireland

Takeda Pharmaceutical Company held a groundbreaking ceremony for its new production facility at the existing Grange Castle site in Ireland. Construction on the new facility will begin in June 2017, the company announced in a press release. Takeda’s existing footprint at the Grange Castle site will be expanded with the construction of a new standalone, high-containment production facility dedicated to manufacturing its oncology product Ninlaro (ixazomib) for global markets.

The plant is scheduled to be completed and become operational to commence shipment of secondary packaged product in 2018. The investment will create approximately 40 new jobs over the next two years. The new production facility will house the drug substance, drug product, primary and secondary packaging, and quality control processes all under one roof.

Ninlaro, a once-weekly oral proteasome inhibitor, was approved in November 2015 by FDA and by the Japanese Ministry of Health, Labour and Welfare in March 2017. The drug has also been approved by the European Commission, and Takeda has submitted applications for approval to multiple other regulatory authorities around the world.

Source: Takeda